Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients

Overexpression of several members of the kallikrein-related peptidase (KLK) family, including KLK4, has been reported in ovarian cancer tissue, consistent with the fact that elevated levels of KLK protein are often also found in serum and in effusion fluids of ovarian cancer patients. In the present...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 14; no. 2; p. e0212968
Main Authors: Gong, Weiwei, Liu, Yueyang, Seidl, Christof, Dreyer, Tobias, Drecoll, Enken, Kotzsch, Matthias, Bronger, Holger, Dorn, Julia, Magdolen, Viktor
Format: Journal Article
Language:English
Published: United States Public Library of Science 27.02.2019
Public Library of Science (PLoS)
Subjects:
Adult
Aged
Aged, 80 and over
Analysis
Ascites
Biology and Life Sciences
Cancer patients
Cancer research
Care and treatment
Cystadenocarcinoma, Serous - genetics
Cystadenocarcinoma, Serous - pathology
Female
Gene Expression Regulation, Neoplastic
Genomes
Genomics
Health aspects
Humans
Kallikrein
Kallikreins - genetics
Medical research
Medicine and Health Sciences
Messenger RNA
Middle Aged
Multivariate Analysis
Neoplasm Grading
Ovarian cancer
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Physical Sciences
Prognosis
Regression analysis
Research and Analysis Methods
RNA
Survival Analysis
Tumors
Up-Regulation
Germany
ISSN:1932-6203, 1932-6203
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Overexpression of several members of the kallikrein-related peptidase (KLK) family, including KLK4, has been reported in ovarian cancer tissue, consistent with the fact that elevated levels of KLK protein are often also found in serum and in effusion fluids of ovarian cancer patients. In the present study, we quantitatively analyzed KLK4 tumor tissue mRNA expression levels in a homogeneous cohort including 138 patients of advanced high-grade serous ovarian cancer (FIGO stage III/IV). Age as well as ascites fluid volume were found to be significantly associated with KLK4 mRNA expression levels. In univariate Cox regression analysis, the clinical factors residual tumor mass and ascites fluid volume represented univariate predictors for both overall survival (OS) and progression-free survival (PFS). Furthermore, elevated KLK4 mRNA expression levels were significantly linked with reduced OS (p = 0.001), but not with PFS. The results concerning the association of KLK4 mRNA expression with OS were validated in a publicly available Affymetrix-based mRNA data set from The Cancer Genome Atlas (n = 252) applying the Kaplan-Meier Plotter tool (p = 0.047). In multivariable analyses, elevated KLK4 mRNA values turned out as an additional, independent predictive marker for shortened OS (p = 0.006), whereas residual tumor mass, but not ascites fluid volume, remained an independent indicator for both OS and PFS (p < 0.001 and p = 0.002, respectively). The results of the present study, obtained in a well-defined, homogenous cohort of patients afflicted with advanced high-grade serous ovarian cancer, are in line with previous reports describing high KLK4 levels as an unfavorable marker in ovarian cancer patients.
AbstractList Overexpression of several members of the kallikrein-related peptidase (KLK) family, including KLK4, has been reported in ovarian cancer tissue, consistent with the fact that elevated levels of KLK protein are often also found in serum and in effusion fluids of ovarian cancer patients. In the present study, we quantitatively analyzed KLK4 tumor tissue mRNA expression levels in a homogeneous cohort including 138 patients of advanced high-grade serous ovarian cancer (FIGO stage III/IV). Age as well as ascites fluid volume were found to be significantly associated with KLK4 mRNA expression levels. In univariate Cox regression analysis, the clinical factors residual tumor mass and ascites fluid volume represented univariate predictors for both overall survival (OS) and progression-free survival (PFS). Furthermore, elevated KLK4 mRNA expression levels were significantly linked with reduced OS (p = 0.001), but not with PFS. The results concerning the association of KLK4 mRNA expression with OS were validated in a publicly available Affymetrix-based mRNA data set from The Cancer Genome Atlas (n = 252) applying the Kaplan-Meier Plotter tool (p = 0.047). In multivariable analyses, elevated KLK4 mRNA values turned out as an additional, independent predictive marker for shortened OS (p = 0.006), whereas residual tumor mass, but not ascites fluid volume, remained an independent indicator for both OS and PFS (p < 0.001 and p = 0.002, respectively). The results of the present study, obtained in a well-defined, homogenous cohort of patients afflicted with advanced high-grade serous ovarian cancer, are in line with previous reports describing high KLK4 levels as an unfavorable marker in ovarian cancer patients.
Overexpression of several members of the kallikrein-related peptidase (KLK) family, including KLK4, has been reported in ovarian cancer tissue, consistent with the fact that elevated levels of KLK protein are often also found in serum and in effusion fluids of ovarian cancer patients. In the present study, we quantitatively analyzed KLK4 tumor tissue mRNA expression levels in a homogeneous cohort including 138 patients of advanced high-grade serous ovarian cancer (FIGO stage III/IV). Age as well as ascites fluid volume were found to be significantly associated with KLK4 mRNA expression levels. In univariate Cox regression analysis, the clinical factors residual tumor mass and ascites fluid volume represented univariate predictors for both overall survival (OS) and progression-free survival (PFS). Furthermore, elevated KLK4 mRNA expression levels were significantly linked with reduced OS (p = 0.001), but not with PFS. The results concerning the association of KLK4 mRNA expression with OS were validated in a publicly available Affymetrix-based mRNA data set from The Cancer Genome Atlas (n = 252) applying the Kaplan-Meier Plotter tool (p = 0.047). In multivariable analyses, elevated KLK4 mRNA values turned out as an additional, independent predictive marker for shortened OS (p = 0.006), whereas residual tumor mass, but not ascites fluid volume, remained an independent indicator for both OS and PFS (p < 0.001 and p = 0.002, respectively). The results of the present study, obtained in a well-defined, homogenous cohort of patients afflicted with advanced high-grade serous ovarian cancer, are in line with previous reports describing high KLK4 levels as an unfavorable marker in ovarian cancer patients.Overexpression of several members of the kallikrein-related peptidase (KLK) family, including KLK4, has been reported in ovarian cancer tissue, consistent with the fact that elevated levels of KLK protein are often also found in serum and in effusion fluids of ovarian cancer patients. In the present study, we quantitatively analyzed KLK4 tumor tissue mRNA expression levels in a homogeneous cohort including 138 patients of advanced high-grade serous ovarian cancer (FIGO stage III/IV). Age as well as ascites fluid volume were found to be significantly associated with KLK4 mRNA expression levels. In univariate Cox regression analysis, the clinical factors residual tumor mass and ascites fluid volume represented univariate predictors for both overall survival (OS) and progression-free survival (PFS). Furthermore, elevated KLK4 mRNA expression levels were significantly linked with reduced OS (p = 0.001), but not with PFS. The results concerning the association of KLK4 mRNA expression with OS were validated in a publicly available Affymetrix-based mRNA data set from The Cancer Genome Atlas (n = 252) applying the Kaplan-Meier Plotter tool (p = 0.047). In multivariable analyses, elevated KLK4 mRNA values turned out as an additional, independent predictive marker for shortened OS (p = 0.006), whereas residual tumor mass, but not ascites fluid volume, remained an independent indicator for both OS and PFS (p < 0.001 and p = 0.002, respectively). The results of the present study, obtained in a well-defined, homogenous cohort of patients afflicted with advanced high-grade serous ovarian cancer, are in line with previous reports describing high KLK4 levels as an unfavorable marker in ovarian cancer patients.
Audience Academic
Author Gong, Weiwei
Liu, Yueyang
Dreyer, Tobias
Dorn, Julia
Drecoll, Enken
Kotzsch, Matthias
Seidl, Christof
Magdolen, Viktor
Bronger, Holger
AuthorAffiliation 2 Institute of Pathology, Technical University of Munich, Munich, Germany
3 Medizinisches Labor Ostsachsen, Dresden, Germany
1 Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
Universidade de Sao Paulo Instituto de Quimica, BRAZIL
AuthorAffiliation_xml – name: 1 Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
– name: 3 Medizinisches Labor Ostsachsen, Dresden, Germany
– name: Universidade de Sao Paulo Instituto de Quimica, BRAZIL
– name: 2 Institute of Pathology, Technical University of Munich, Munich, Germany
Author_xml – sequence: 1
  givenname: Weiwei
  surname: Gong
  fullname: Gong, Weiwei
– sequence: 2
  givenname: Yueyang
  surname: Liu
  fullname: Liu, Yueyang
– sequence: 3
  givenname: Christof
  surname: Seidl
  fullname: Seidl, Christof
– sequence: 4
  givenname: Tobias
  surname: Dreyer
  fullname: Dreyer, Tobias
– sequence: 5
  givenname: Enken
  surname: Drecoll
  fullname: Drecoll, Enken
– sequence: 6
  givenname: Matthias
  surname: Kotzsch
  fullname: Kotzsch, Matthias
– sequence: 7
  givenname: Holger
  surname: Bronger
  fullname: Bronger, Holger
– sequence: 8
  givenname: Julia
  surname: Dorn
  fullname: Dorn, Julia
– sequence: 9
  givenname: Viktor
  orcidid: 0000-0003-0167-793X
  surname: Magdolen
  fullname: Magdolen, Viktor
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30811511$$D View this record in MEDLINE/PubMed
BookMark eNp9kl2L1DAUhousuB_6D0QC3qwXHZuPSVsvFobBj2UHBdn7kCYnM5ltk5q0g_on_MumO-OyIyK5SDh53vechPc8O3HeQZa9xMUM0xK_3foxONnO-lSeFQSTmldPsjNcU5JzUtCTR-fT7DzGbVHMacX5s-yUFhXGc4zPsl_LjQxSDRDsTzlY75A36E62rb0LYF0eoJUDaNRDP1gtIyCGLm9WN-wN6r5-XiD43geIcRJah4ax8wENNsYRJiOpd9KpJN_Y9SZfB6kBRQh-jMjvZLDSITUBAfWpObghPs-eGtlGeHHYL7LbD-9vl5_y1ZeP18vFKldzhod8zupaKV2T0jTYNFAxbkylZW2aAkrSUAVM0wYDV7UmQKkkzODGYFVhU1b0Irve22ovt6IPtpPhh_DSivuCD2shw2BVC8JoSjjlhJHURTEtlQKMWcUKXpFS6uR1tffqx6YDrdIzgmyPTI9vnN2Itd8JTmtCSpIMLg8GwX8bIQ6is1FB20oH6asEwVVZkLLgdUJf79G1TKNZZ3xyVBMuFvOSY8YoLRM1-weVlobOqpQXY1P9SPDq8RMeZv-TkwSwPaCCjzGAeUBwIaY4ikMcxRRHcYhjkr37S6bscB-zNJBt_y_-DfPv7MI
CitedBy_id crossref_primary_10_2147_CMAR_S241372
crossref_primary_10_1186_s13048_020_00725_5
crossref_primary_10_1080_14728222_2024_2415014
crossref_primary_10_1107_S2059798321006483
crossref_primary_10_1038_s41568_021_00436_z
crossref_primary_10_1016_j_bbrc_2023_149217
crossref_primary_10_1038_s41420_021_00631_9
crossref_primary_10_1016_j_cca_2023_117618
crossref_primary_10_1080_14737159_2021_1924680
crossref_primary_10_1164_rccm_202407_1290ED
Cites_doi 10.1038/sj.bjc.6605280
10.2217/WHE.14.4
10.1515/hsz-2017-0122
10.1038/s41416-018-0260-1
10.1160/TH13-03-0206
10.1016/j.ygyno.2007.01.018
10.1016/j.ygyno.2004.03.044
10.1016/j.biochi.2015.09.002
10.1016/j.ygyno.2012.09.001
10.1530/ERC-11-0329
10.1002/pros.21395
10.1515/BC.2001.002
10.1515/hsz-2014-0139
10.1016/j.biomaterials.2013.06.009
10.1371/journal.pone.0057056
10.1016/j.molonc.2013.09.003
10.1515/BC.2009.026
10.1038/sj.bjc.6600323
10.1515/hsz-2016-0177
10.1309/PTBB5BPCKX8K9V69
10.1016/j.canlet.2006.12.018
10.1080/14728222.2018.1512587
10.1002/pros.20101
10.1097/AOG.0b013e318264f794
10.3322/caac.20107
10.1515/hsz-2014-0149
10.1515/BC.2006.029
10.3322/caac.21387
10.2478/raon-2013-0053
10.1007/s13577-015-0114-6
10.1158/0008-5472.CAN-09-3415
10.1038/nrc1474
10.1371/journal.pone.0186847
10.3892/ol.2011.291
10.1371/journal.pone.0026075
10.1210/er.2009-0034
10.1309/0UA57MNAYV0MCE9U
10.1016/S0002-9440(10)63306-8
10.1111/j.1742-4658.2008.06265.x
10.1515/hsz-2011-0260
10.1159/000094741
ContentType Journal Article
Copyright COPYRIGHT 2019 Public Library of Science
2019 Gong et al 2019 Gong et al
Copyright_xml – notice: COPYRIGHT 2019 Public Library of Science
– notice: 2019 Gong et al 2019 Gong et al
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1371/journal.pone.0212968
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Acceso a contenido Full Text - Doaj
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Acceso a contenido Full Text - Doaj
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
DocumentTitleAlternate KLK4 mRNA expression in advanced high-grade serous ovarian cancer
EISSN 1932-6203
ExternalDocumentID oai_doaj_org_article_fd32636242e84c4dacce1148406827ad
PMC6392272
A576144337
30811511
10_1371_journal_pone_0212968
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Germany
GeographicLocations_xml – name: Germany
GrantInformation_xml – fundername: ;
  grantid: 2016-024.1
– fundername: ;
  grantid: BR 4733/3-1
– fundername: ;
  grantid: AV 109/74-1
– fundername: ;
  grantid: DO 1772/1–1
– fundername: ;
  grantid: MA 1236/10-1
GroupedDBID ---
123
29O
2WC
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABIVO
ABJCF
ABUWG
ACCTH
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AEUYN
AFFHD
AFKRA
AFPKN
AFRAH
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAIFH
BAWUL
BBNVY
BBTPI
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
EMOBN
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IGS
IHR
IHW
INH
INR
IOV
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
P62
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PTHSS
PV9
PYCSY
RNS
RPM
RZL
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
3V.
ADRAZ
ALIPV
BBORY
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
7X8
ESTFP
PUEGO
5PM
ID FETCH-LOGICAL-c541t-5499ccd927fb1fbe846ff8da9fb0e72b3ce4d3b1e6c9d2e33a24f1bf1c81f783
IEDL.DBID DOA
ISICitedReferencesCount 15
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000459806400101&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1932-6203
IngestDate Tue Oct 14 19:00:24 EDT 2025
Tue Nov 04 01:58:44 EST 2025
Mon Sep 08 15:42:08 EDT 2025
Sat Nov 29 13:06:11 EST 2025
Sat Nov 29 10:17:48 EST 2025
Wed Feb 19 02:31:02 EST 2025
Sat Nov 29 03:32:35 EST 2025
Tue Nov 18 22:27:14 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-5499ccd927fb1fbe846ff8da9fb0e72b3ce4d3b1e6c9d2e33a24f1bf1c81f783
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
ORCID 0000-0003-0167-793X
OpenAccessLink https://doaj.org/article/fd32636242e84c4dacce1148406827ad
PMID 30811511
PQID 2187027069
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_fd32636242e84c4dacce1148406827ad
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6392272
proquest_miscellaneous_2187027069
gale_infotracmisc_A576144337
gale_infotracacademiconefile_A576144337
pubmed_primary_30811511
crossref_primary_10_1371_journal_pone_0212968
crossref_citationtrail_10_1371_journal_pone_0212968
PublicationCentury 2000
PublicationDate 2019-02-27
PublicationDateYYYYMMDD 2019-02-27
PublicationDate_xml – month: 02
  year: 2019
  text: 2019-02-27
  day: 27
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco, CA USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2019
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References H Shahinian (ref46) 2014; 8
Y Dong (ref12) 2010; 70
Y Dong (ref13) 2013; 8
B Gyorffy (ref32) 2012; 19
S Mukai (ref45) 2015; 28
OL Tan (ref7) 2006; 387
LY Luo (ref15) 2002; 86
S Mukai (ref44) 2008; 275
D Loessner (ref24) 2012; 127
K Hibbs (ref28) 2004; 165
CA Borgoño (ref17) 2004; 4
D Loessner (ref14) 2013; 34
Y Dong (ref27) 2001; 7
P Wang (ref48) 2018; 119
J Dorn (ref9) 2013; 110
J Clements (ref5) 2001; 382
M Paliouras (ref6) 2007; 249
E Foteinou (ref37) 2014; 395
D Loessner (ref41) 2018; 22
W Pfaffl (ref30) 2012
H Yoon (ref49) 2009; 390
CV Obiezu (ref29) 2001; 7
S IeM (ref19) 2007; 105
RL Siegel (ref1) 2017; 67
A Bustin (ref31) 2013
M Avgeris (ref34) 2011; 71
M Avgeris (ref8) 2012; 393
M Matsumura (ref43) 2005; 62
D Pépin (ref20) 2011; 6
M Schmitt (ref10) 2013; 47
T Kryza (ref40) 2016; 122
Y Dong (ref21) 2003; 9
N Han (ref47) 2011; 2
LA Baldwin (ref3) 2012; 120
A Jemal (ref2) 2011; 61
N Beaufort (ref42) 2006; 387
F Yang (ref36) 2017; 398
X Geng (ref26) 2017; 12
GM Yousef (ref16) 2003; 63
P Papagerakis (ref35) 2015; 35
MG Lawrence (ref39) 2010; 31
H Jin (ref18) 2006; 27
N Ahmed (ref25) 2016; 397
Z Xi (ref38) 2004; 94
M Pölcher (ref4) 2014; 10
J Lai (ref11) 2014; 395
B Davidson (ref33) 2005; 123
NM White (ref23) 2009; 101
GM Yousef (ref22) 2003; 119
References_xml – volume: 101
  start-page: 1107
  year: 2009
  ident: ref23
  article-title: KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605280
– volume: 10
  start-page: 179
  year: 2014
  ident: ref4
  article-title: Cytoreductive surgery for advanced ovarian cancer
  publication-title: Womens Health (Lond)
  doi: 10.2217/WHE.14.4
– volume: 398
  start-page: 1151
  year: 2017
  ident: ref36
  article-title: Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer
  publication-title: Biol Chem
  doi: 10.1515/hsz-2017-0122
– volume: 119
  start-page: 1
  year: 2018
  ident: ref48
  article-title: Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer
  publication-title: Br J Cancer
  doi: 10.1038/s41416-018-0260-1
– volume: 110
  start-page: 408
  year: 2013
  ident: ref9
  article-title: Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies
  publication-title: Thromb Haemost
  doi: 10.1160/TH13-03-0206
– volume: 105
  start-page: 501
  year: 2007
  ident: ref19
  article-title: Ovarian cancer specific kallikrein profile in effusions
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2007.01.018
– volume: 94
  start-page: 80
  year: 2004
  ident: ref38
  article-title: Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2004.03.044
– volume: 122
  start-page: 283
  year: 2016
  ident: ref40
  article-title: The kallikrein-related peptidase family: Dysregulation and functions during cancer progression
  publication-title: Biochimie
  doi: 10.1016/j.biochi.2015.09.002
– volume: 127
  start-page: 569
  year: 2012
  ident: ref24
  article-title: Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2012.09.001
– volume: 19
  start-page: 197
  year: 2012
  ident: ref32
  article-title: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
  publication-title: Endocr Relat Cancer
  doi: 10.1530/ERC-11-0329
– volume: 71
  start-page: 1780
  year: 2011
  ident: ref34
  article-title: Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance
  publication-title: Prostate
  doi: 10.1002/pros.21395
– volume: 382
  start-page: 5
  year: 2001
  ident: ref5
  article-title: The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions
  publication-title: Biol Chem
  doi: 10.1515/BC.2001.002
– volume: 395
  start-page: 1051
  year: 2014
  ident: ref37
  article-title: Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma
  publication-title: Biol Chem
  doi: 10.1515/hsz-2014-0139
– volume: 34
  start-page: 7389
  year: 2013
  ident: ref14
  article-title: A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2013.06.009
– volume: 8
  start-page: e57056
  year: 2013
  ident: ref13
  article-title: Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0057056
– volume: 387
  start-page: 697
  year: 2006
  ident: ref7
  article-title: Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function
  publication-title: Biol Chem
– volume: 8
  start-page: 68
  year: 2014
  ident: ref46
  article-title: Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells
  publication-title: Mol Oncol
  doi: 10.1016/j.molonc.2013.09.003
– start-page: 53
  year: 2012
  ident: ref30
  article-title: quantitative real-time PCR in applied microbiology
– volume: 390
  start-page: 373
  year: 2009
  ident: ref49
  article-title: A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15
  publication-title: Biol Chem
  doi: 10.1515/BC.2009.026
– volume: 86
  start-page: 1790
  year: 2002
  ident: ref15
  article-title: Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6600323
– volume: 397
  start-page: 1265
  year: 2016
  ident: ref25
  article-title: Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer
  publication-title: Biol Chem
  doi: 10.1515/hsz-2016-0177
– volume: 63
  start-page: 2223
  year: 2003
  ident: ref16
  article-title: Parallel overexpression of seven kallikrein genes in ovarian cancer
  publication-title: Cancer Res
– start-page: 51
  year: 2013
  ident: ref31
  article-title: Real-time PCR: advanced technologies and applications
– volume: 123
  start-page: 360
  year: 2005
  ident: ref33
  article-title: Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
  publication-title: Am J Clin Pathol
  doi: 10.1309/PTBB5BPCKX8K9V69
– volume: 35
  start-page: 1861
  year: 2015
  ident: ref35
  article-title: Clinical significance of kallikrein-related peptidase-4 in oral cancer
  publication-title: Anticancer Res
– volume: 249
  start-page: 61
  year: 2007
  ident: ref6
  article-title: Human tissue kallikreins: the cancer biomarker family
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2006.12.018
– volume: 22
  start-page: 745
  year: 2018
  ident: ref41
  article-title: Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer
  publication-title: Expert Opin Ther Targets
  doi: 10.1080/14728222.2018.1512587
– volume: 62
  start-page: 1
  year: 2005
  ident: ref43
  article-title: Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries
  publication-title: Prostate
  doi: 10.1002/pros.20101
– volume: 120
  start-page: 612
  year: 2012
  ident: ref3
  article-title: Ten-year relative survival for epithelial ovarian cancer
  publication-title: Obstet Gynecol
  doi: 10.1097/AOG.0b013e318264f794
– volume: 61
  start-page: 69
  year: 2011
  ident: ref2
  article-title: Global cancer statistics
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20107
– volume: 9
  start-page: 1710
  year: 2003
  ident: ref21
  article-title: Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers
  publication-title: Clin Cancer Res
– volume: 395
  start-page: 1127
  year: 2014
  ident: ref11
  article-title: Analysis of androgen and anti-androgen regulation of KLK-related peptidase 2, 3, and 4 alternative transcripts in prostate cancer
  publication-title: Biol Chem
  doi: 10.1515/hsz-2014-0149
– volume: 387
  start-page: 217
  year: 2006
  ident: ref42
  article-title: Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR)
  publication-title: Biol Chem
  doi: 10.1515/BC.2006.029
– volume: 67
  start-page: 7
  year: 2017
  ident: ref1
  article-title: Cancer Statistics, 2017
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21387
– volume: 47
  start-page: 319
  year: 2013
  ident: ref10
  article-title: Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies
  publication-title: Radiol Oncol
  doi: 10.2478/raon-2013-0053
– volume: 28
  start-page: 133
  year: 2015
  ident: ref45
  article-title: Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis
  publication-title: Hum Cell
  doi: 10.1007/s13577-015-0114-6
– volume: 70
  start-page: 2624
  year: 2010
  ident: ref12
  article-title: Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-3415
– volume: 4
  start-page: 876
  year: 2004
  ident: ref17
  article-title: The emerging roles of human tissue kallikreins in cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1474
– volume: 12
  start-page: e0186847
  year: 2017
  ident: ref26
  article-title: Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0186847
– volume: 2
  start-page: 599
  year: 2011
  ident: ref47
  article-title: Protease-activated receptors in cancer: A systematic review
  publication-title: Oncol Lett
  doi: 10.3892/ol.2011.291
– volume: 6
  start-page: e26075
  year: 2011
  ident: ref20
  article-title: Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0026075
– volume: 31
  start-page: 407
  year: 2010
  ident: ref39
  article-title: Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus
  publication-title: Endocr Rev
  doi: 10.1210/er.2009-0034
– volume: 119
  start-page: 346
  year: 2003
  ident: ref22
  article-title: Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer
  publication-title: Am J Clin Pathol
  doi: 10.1309/0UA57MNAYV0MCE9U
– volume: 165
  start-page: 397
  year: 2004
  ident: ref28
  article-title: Differential gene expression in ovarian carcinoma: identification of potential biomarkers
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)63306-8
– volume: 7
  start-page: 2363
  year: 2001
  ident: ref27
  article-title: Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas
  publication-title: Clin Cancer Res
– volume: 275
  start-page: 1003
  year: 2008
  ident: ref44
  article-title: Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases
  publication-title: FEBS J
  doi: 10.1111/j.1742-4658.2008.06265.x
– volume: 393
  start-page: 301
  year: 2012
  ident: ref8
  article-title: Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance
  publication-title: Biol Chem
  doi: 10.1515/hsz-2011-0260
– volume: 27
  start-page: 274
  year: 2006
  ident: ref18
  article-title: Expression of tumor-associated differentially expressed Gene-14 (TADG-14/KLK8) and its protein hK8 in uterine endometria and endometrial carcinomas
  publication-title: Tumour Biol
  doi: 10.1159/000094741
– volume: 7
  start-page: 2380
  year: 2001
  ident: ref29
  article-title: Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients
  publication-title: Clin Cancer Res
SSID ssj0053866
Score 2.3842263
Snippet Overexpression of several members of the kallikrein-related peptidase (KLK) family, including KLK4, has been reported in ovarian cancer tissue, consistent with...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e0212968
SubjectTerms Adult
Aged
Aged, 80 and over
Analysis
Ascites
Biology and Life Sciences
Cancer patients
Cancer research
Care and treatment
Cystadenocarcinoma, Serous - genetics
Cystadenocarcinoma, Serous - pathology
Female
Gene Expression Regulation, Neoplastic
Genomes
Genomics
Health aspects
Humans
Kallikrein
Kallikreins - genetics
Medical research
Medicine and Health Sciences
Messenger RNA
Middle Aged
Multivariate Analysis
Neoplasm Grading
Ovarian cancer
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Physical Sciences
Prognosis
Regression analysis
Research and Analysis Methods
RNA
Survival Analysis
Tumors
Up-Regulation
Title Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients
URI https://www.ncbi.nlm.nih.gov/pubmed/30811511
https://www.proquest.com/docview/2187027069
https://pubmed.ncbi.nlm.nih.gov/PMC6392272
https://doaj.org/article/fd32636242e84c4dacce1148406827ad
Volume 14
WOSCitedRecordID wos000459806400101&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: Acceso a contenido Full Text - Doaj
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: DOA
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M~E
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Advanced Technologies & Aerospace Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: P5Z
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/hightechjournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Agricultural Science Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M0K
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/agriculturejournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Biological Science Database (ProQuest)
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M7P
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Engineering Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: M7S
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Environmental Science Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: PATMY
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/environmentalscience
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection (ProQuest)
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: 7X7
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Materials Science Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: KB.
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/materialsscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Nursing & Allied Health Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: 7RV
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/nahs
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: BENPR
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database (ProQuest)
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: 8C1
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: PIMPY
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVATS
  databaseName: Public Library of Science (PLoS) Journals Open Access
  customDbUrl:
  eissn: 1932-6203
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053866
  issn: 1932-6203
  databaseCode: FPL
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://www.plos.org/publications/
  providerName: Public Library of Science
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF5B4cAFUZ6GEi0SEu3Bqe11PPYxiRqB0kZWqFDgYtn7gKipEzlJxb_gLzNjb6JYHHrhMgfv2l7PY2dGnvmWsY-9yAglIHELE3tuKAD3QZkULrpzH2QMAry8PmwCJpN4NkvSg6O-qCasgQduGHduFAYYgroYdBzKUOVSaorh0RHFAeSKdl8Pkl0y1ezBaMVRZBvlBPjnVi7d1bLUXQI1Twha9cAR1Xj9_-7KB26pXTJ54INGz9hTGzzyfrPoY_ZAl8_ZsTXPNT-1GNJnL9if4R6Iuemz5EvDb_LFYn5T6Xnp1i0sWvEVFbUo9GQ85Kfjy3F4xm-nkz7Xv22BbMnnJd9sb5cV39QyogftCgc4gR27P6tcaY6qvNyu-fIOk--85JImVNzCtq5fsuvRxfXws2vPXnBlL_Q3LqWNUqokAFP4pkDeR8bEKk9M4WkICiF1qETh60gmKtBC5EFo_ML4MvYNxOIVOyqR2W8YNzqINWjlF5LacDHlFpJQ4wvoARgROUzs5JBJi0tOx2MssvpnG2B-0nA3I-llVnoOc_d3rRpcjnvmD0jE-7mEql1fQF3LrK5l9-mawz6RgmRk-7hEmdsWBnwPoWhlfUzeMEEVAhx20pqJNitbwx92KpbREBW6lRqllGHEBV4AXpQ47HWjcvs1CwzfMEDzHQYtZWx9VHuknP-qIcMxDg0CCN7-Dy68Y08wakzqvn44YUebaqvfs8fyDtWw6rCHMP1GdAY1jZHGQ7_DHg0uJum0U9sp0lF6iXQ86CK98sZEIa3pV6Rp7wfekX65Sr__BbYQSRk
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+kallikrein-related+peptidase+4+%28KLK4%29+mRNA+expression+in+tumor+tissue+of+advanced+high-grade+serous+ovarian+cancer+patients&rft.jtitle=PloS+one&rft.au=Gong%2C+Weiwei&rft.au=Liu%2C+Yueyang&rft.au=Seidl%2C+Christof&rft.au=Dreyer%2C+Tobias&rft.date=2019-02-27&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=14&rft.issue=2&rft.spage=e0212968&rft_id=info:doi/10.1371%2Fjournal.pone.0212968&rft.externalDBID=n%2Fa&rft.externalDocID=10_1371_journal_pone_0212968
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon